Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.
Ciaccio C, Goldsobel AB, Anagnostou A, Beyer K, Casale TB, Deschildre A, Fernández-Rivas M, Hourihane JO, Krawiec M, Lieberman J, Scurlock AM, Vickery BP, Smith A, Tilles SA, Adelman DC, Brown KR; RAMSES (ARC007) and ARC011 Study Groups:.
Ciaccio C, et al.
Ann Allergy Asthma Immunol. 2022 Dec;129(6):758-768.e4. doi: 10.1016/j.anai.2022.07.033. Epub 2022 Aug 13.
Ann Allergy Asthma Immunol. 2022.
PMID: 35973655
Free article.
Clinical Trial.
ARC011 was the subsequent 6-month follow-on maintenance PTAH study. The primary end point for RAMSES and ARC011 was the frequency of treatment-emergent adverse events (AEs). We descriptively compared baseline characteristics and safety outcomes from RAMSES and ARC01 …
ARC011 was the subsequent 6-month follow-on maintenance PTAH study. The primary end point for RAMSES and ARC011 was the frequency of …